Back to Journals » Open Access Rheumatology: Research and Reviews » Volume 5

Retrospective analysis of the clinical course of patients treated for polymyalgia

Authors Do-Nguyen D, Inderjeeth CA, Edelman J, Cheah P

Received 23 September 2012

Accepted for publication 17 January 2013

Published 26 April 2013 Volume 2013:5 Pages 33—41

DOI https://doi.org/10.2147/OARRR.S38443

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3


Dung Do-Nguyen,1 Charles A Inderjeeth,1–3 Jack Edelman,2 Patrick Cheah2

1Rehabilitation and Aged Care, North Metropolitan Health Service, 2Department of Rheumatology, Sir Charles Gairdner Hospital, 3Faculty of Medicine and Pharmacology, The University of Western Australia, Perth, WA, Australia

Background: Polymyalgia rheumatica is a chronic inflammatory rheumatic condition, for which the mainstay of treatment is corticosteroids. Here, we review the clinical course of treated patients initially presenting with polymyalgic symptoms.
Methods: A retrospective audit was performed of patients who presented with a possible diagnosis of polymyalgia rheumatica. Biochemical markers and prednisone doses were assessed at the initial review, at one month, and 3, 6, and 12 months later.
Results: A cohort of 135 patients was identified, comprising 91 females and 44 males of mean age 70.7 years. All patients were treated with oral prednisone at an initial mean dose of 21.3 mg. Mean baseline C-reactive protein level and erythrocyte sedimentation rate were 41.6 mg/L and 48.6 mm/hour, respectively. Following initiation of therapy, there was a dramatic and sustained decrease in both inflammatory markers. A clinical response was observed in 96.2% of patients, but remission was achieved in only 18.2%. Of those initially diagnosed with polymyalgia rheumatica, 24.8% were subsequently diagnosed with a different rheumatic condition.
Conclusion: The excellent response rate to corticosteroid therapy is well established in the literature, but in this research, remission rates were comparatively low during the 12-month study period. The current value of disease-modifying antirheumatic drugs and biologic therapy appears uncertain, and further trials to establish their precise role would be beneficial. A large portion of patients presenting with polymyalgia were eventually diagnosed to have another rheumatic disease, thus reflecting the broad differential diagnosis of polymyalgia symptoms. Polymyalgia symptoms can occur in patients with polymyalgia rheumatica and other rheumatic conditions. This group has a good response to prednisone therapy, although remission at 12 months appears to be uncommon. The gold standard of treatment remains corticosteroid therapy.

Keywords: polymyalgia rheumatica, diagnosis, treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]